Uwe Reuter (Charité Universitätsmedizin Berlin, Germany) talks to us about the first head-to-head randomized, double-blind, double-dummy trial of erenumab and topiramate for the prevention of episodic and chronic migraine (ClinicalTrials.gov Identifier: NCT03828539).
Questions
1. What are the unmet needs in the treatment of episodic migraine? (0:05)
2. Could you tell us a little about the objectives and design of the HER-MES study of erenumab vs topiramate? (1:13)
3. What have been the findings of the study so far? (3:10)
4. What has been the impact of antibodies targeting calcitonin gene-related peptide (CGRP) on the treatment landscape for episodic migraine? (4:44)
5. How do you see the treatment of episodic migraine progressing in the next 5 years? (6:50)
Speaker disclosure: Uwe Reuter reports having received honoraria for consulting and lectures within the past 3 years from Amgen, PharmAllergan, Eli Lilly, Lundbeck, Novartis Pharma, Hormosan Pharma, electroCore, Medscape, Novartis, StreaMedUp and Teva, he holds no stocks of pharmaceutical companies or medical device companies.
Support: Interview and filming supported by Touch Medical Media.
Filmed at the 6th Congress of the European Academy of Neurology (EAN) and 1st EAN Virtual Congress, May 2020.
